IgG Fc glycome as a checkpoint for antitumor immunity

Anti-tumor antibodies are being produced in patients with different cancer types. Yet, they fail to mediate effective clearance of the tumor cells and to engage efficient anti-tumor immune response. We hypothesize that the Fc-glycan repertoire is a key determinant that regulate the anti-tumor antibody response. Here, we propose to develop mass-spectrometry based assay to characterize the IgG Fc-glycome in patients and mouse models of different cancer types.